Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Natalia Roson-CaleroBarcelona Institute for Global Health (ISGlobal), Barcelona, Spain.ORCID 0000-0002-3005-9981
María A Gomis FontCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Albert Ruiz-SorianoLaboratori de Química Orgànica, Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain.
Xavier Just-BaringoLaboratori de Química Orgànica, Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain.
María Eugenia Pachón-IbáñezCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
J Pablo SalvadorNanobiotechnology for Diagnostics (Nb4D), Department of Chemical and Biomolecular Nanotechnology, Institute for Advanced Architecture of Catalonia (IQAC) of the Spanish Council for Scientific Research (CSIC), Barcelona, Spain.
M Pilar MarcoNanobiotechnology for Diagnostics (Nb4D), Department of Chemical and Biomolecular Nanotechnology, Institute for Advanced Architecture of Catalonia (IQAC) of the Spanish Council for Scientific Research (CSIC), Barcelona, Spain.ORCID 0000-0002-4064-1668
Ernest GiraltInstitute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.
Antonio OliverCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0001-9327-1894
Clara Ballesté-DelpierreCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0001-8589-2519
Jordi VilaBarcelona Institute for Global Health (ISGlobal), Barcelona, Spain.ORCID 0000-0002-8025-3926
Funding
Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas (CIBERINFEC) IM22/INF/4Government of Catalonia | Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) 2021 SGR0 1569MEC | Instituto de Salud Carlos III (ISCIII) PI21/00017Ministerio de Ciencia e Innovación (MCIN) CEX2018-000806-SMinisterio de Ciencia e Innovación (MCIN) PID2022-139257NB-I00
6 · The paper itself
Abstract
The pipeline for new drugs against multidrug-resistant
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.